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5 patients, 1 died 3 days after diagnosis. 4 patients had 
surgery, 3 developed DM and 1 is a long-term survivor. 
Median OS was 68 days. 
 
 
 
Conclusion: These rare sarcomas have variable clinical 
presentations. Surgery is the central component for 
successful treatment but complete resection is not always 
possible. RT may reduce LR (reduced from 77%, group B,to 
53%, group A) and chemotherapy is offered if high risk 
(inoperable, R2 margins, or DM). We still need to define the 
optimum management. 
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Purpose or Objective: To evaluate the impact of a dose 
escalation > 50 Gy in a large series of resected limbs soft 
tissue sarcomas (STS) 
 
Material and Methods: Data were retrospectively analyzed 
from 414 consecutive localized limbs STS patients who 
received irradiation and enlarged surgery at Gustave Roussy 
from 05/1993 to 05/2012. RT dose level were decided in 
multidisciplinary staff and depended upon the quality of 
surgery and margins size. 
 
Results: The median age was 52 years, the median tumor size 
was 89 mm, most patients had proximal locations (72%), and 
G-2-3 tumors (79%). Available histologic analyses after 
surgery retrieved 84% unifocal tumors and free-tumor margins 
>1 mm in 69% of cases. Radiotherapy (RT) was delivered prior 
(13%) or after (87%) surgery. Seven patients (2%) had pre- and 
a postoperative RT boost. Median delivered RT dose was 50 
Gy (36-70 Gy), and 40% received >50Gy. At a median follow-
up of 5.5 years, the 5-year local relapse rates (LRRs) were 
7%, 4%, and 13% in the general population, in patients 
receiving <50Gy and in those who had >50 Gy (p<0.001), 
respectively. Despite this may due to confounding factors, a 
dose >50 Gy (HR: 2.6; p=0.04) remained associated with 
higher LRRs in the multivariate analysis (MVA), as well as 
histological subtypes (HR: 3.7; p=0.002), and surgical 
margins<1mm (HR: 3.2; p=0.008). Grade, age, and tumour 
size were not associated with LRRs in the MVA. 
 
Conclusion: In this retrospective analysis of patients having 
enlarged and surgery and RT dose escalation did not allow 
offsetting local relapse in high-risk patients. This should be 
evaluated in a larger set of patients all having enlarged 
surgery. A Prospective study allowing dose refinement in this 
setting is required. 
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Purpose or Objective: Fluid collection of lymph or blood may 
accumulate at the site of excision after surgery for soft tissue 
sarcoma, with reported incidence rates from 10-36%. Though 
small fluid collections have a high probability of being 
completely covered within the postoperative radiotherapy 
(PORT) field, large fluid collections may require a more 
extensive expansion of CTVs. This study is an unprecedented 
analysis of fluid collection in relation to radiotherapy 
outcomes after wide excision of soft tissue sarcoma (STS). 
 
Material and Methods: Medical records of 151 patients with 
STS treated with wide excision followed by adjuvant PORT 
between 2004 and 2014 were retrospectively reviewed. Only 
non-recurrent and non-metastatic patients were included. 
After evaluation of CT and MR images taken at the time of 
PORT planning, fluid collection was detected in 46 patients 
(30.5%). Because fluid collection developed more commonly 
in lower extremity (p<0.001) and higher grade tumors 
(p=0.095), only these patients were included in further 
analyses (n=76). Fluid collection was present in 35 (46.1%) 
patients, of which 74.3% and 25.7% had, respectively, either 
complete or partial coverage in planning target volumes 
(PTVs) throughout the entire course of PORT. 
 
Results: After a median follow-up of 41 months, patients 
with and without fluid collection demonstrated local failure 
rates of 14.3% and 9.8%, and 5-year local control (LC) rates of 
83.1% and 86.8%, respectively. The presence of fluid 
collection had no statistical impact on the clinical outcomes 
of PORT. Partial coverage of fluid collection showed a low 5-
year LC rate of 77.8% compared with 85.5% and 86.8% for 
patients that had complete PTV coverage or absence of fluid 
collection, respectively, without statistical significance. Post-
PORT complications developed in 5 (6.6%) patients, of which 
4 had fluid collection. Wound complication developed in 3 
(8.6%) of 35 patients with fluid collection and in 1 (2.4%) of 
41 patients without fluid collection. 
 
Conclusion: Fluid collection demonstrated lower LC rates 
after wide excision and PORT for STS, but with a reasonable 
wound complication rate of 8.6% when compared with rates 
of previous studies ranging from 5-17%. Furthermore, partial 
coverage of fluid collections in PTVs had worse LC rates, thus 
recommending complete coverage. Future evaluation wth a 
larger number of cases will be needed for statistical support 
of our findings. 
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